A Phase 3 interventional study of AZ-3102 and Placebo in Niemann-Pick Type C Disease, GM1 Gangliosidosis and GM2 Gangliosidosis, sponsored by Azafaros B.V.. Recruiting at 39 sites in 17 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Azafaros B.V. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Niemann-Pick Disease, Type C with a site in United States — 6 open to participants now, 8 under way, 4 of them phase 3. Niemann-Pick Disease, Type C · United States.
Among the 23 studies in Niemann-Pick Disease, Type C with a site in United States, this one has the largest planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 3, and was the 22nd registered.
37 studies on the registry are indexed under Niemann-Pick Disease, Type C; 8 are open to participants now.
Browse Niemann-Pick Disease, Type C studies →6 of the 23 studies in Niemann-Pick Disease, Type C with a site in United States are open now. Recruiting first, the newest first:
Azafaros B.V. · Sites in United States, Argentina, Australia and 12 more countries
Ages 4+
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 3 mo+
IntraBio Inc · Sites in United States, Australia, Czechia and 5 more countries
Ages 4+
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 1 days–120 yrs · Healthy volunteers
Albert Einstein College of Medicine · Sites in United States
Ages up to 4 wk · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Niemann-Pick Disease, Type C studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.
This study: 4 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 8
First in 2006; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 147 is above the median of 21 across 27 interventional studies indexed under Niemann-Pick Disease, Type C.
Median enrollment 33 across the 17 interventional studies, 900 across the 5 observational. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 23 have an industry lead sponsor. The 10 most frequent:
Azafaros B.V. is the lead sponsor of 8 studies on the registry; 4 are open to participants now.
Azafaros B.V. has 5 studies filed under Niemann-Pick Disease, Type C — fewer than ten, so there is no comparison to draw.
2 of the studies in Niemann-Pick Disease, Type C with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT05588167Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Niemann-Pick Disease, Type C with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An 18-month double-blind, randomized, placebo-controlled, multicenter, Phase 3 study to evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in late-infantile and juvenile forms of Niemann-Pick type C disease and in late-infantile and juvenile-onset forms of GM1 gangliosidosis or GM2 gangliosidosis
This is a Phase 3 randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of oral nizubaglustat (AZ-3102) in multiple disease areas using a Master Protocol Research Program. Participants are randomized to different subprotocols based on disease type: Niemann-Pick type C (NPC), GM1 gangliosidosis or GM2 gangliosidosis.
Treatment specific procedures will be described in the disease-specific subprotocol. Individual subprotocols may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in the corresponding subprotocols.
For information specific to each individual subprotocol included in this trial, please refer to the corresponding, separate, clinicaltrials.gov records: Niemann-Pick type C disease NCT07082725 (Recruiting) and GM1 gangliosidosis or GM2 gangliosidosis NCT07082543 (Active, not recruiting - No longer looking for participants) .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will be randomized to receive either nizubaglustat or placebo at a 2:1 ratio (nizubaglustat:placebo). (Recruiting)
Drug: AZ-3102 · Drug: Placebo
Participants will be randomized to receive either nizubaglustat or placebo at a 2:1 ratio (nizubaglustat:placebo). (Active, not recruiting - No longer looking for participants)
Drug: AZ-3102 · Drug: Placebo
Oral dispersible tablets
Also known as: nizubaglustat
A matching placebo will be administered in the same regimen as the intervention
Number of participants allocated to subprotocol AZA-001-301-NPC
Time frame: Baseline to month 18
Number of participants allocated to subprotocol AZA-001-301-GMx
Time frame: Baseline to month 18
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2025 (actual). Primary completion is estimated for May 2028, 34 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nizubaglustat
Niemann-Pick Disease, Type C →
Azafaros B.V.